{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:23:39Z","timestamp":1770834219187,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejim.2017.07.016","type":"journal-article","created":{"date-parts":[[2017,7,9]],"date-time":"2017-07-09T07:30:15Z","timestamp":1499585415000},"page":"e24-e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability"],"prefix":"10.1016","volume":"44","author":[{"given":"Michele","family":"Correale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Zicchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilenia","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-7408","authenticated-orcid":false,"given":"Natale Daniele","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.07.016_bb0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10741-016-9566-3","article-title":"Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure","volume":"21","author":"Ameri","year":"2016","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2017.07.016_bb0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijcard.2016.12.172","article-title":"Respiratory drive in patients with chronic heart failure and central sleep apnea: data from the Daunia Heart Failure registry","volume":"230","author":"Correale","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0015","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/eci.12520","article-title":"Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry","volume":"45","author":"Correale","year":"2015","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.ejim.2017.07.016_bb0020","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/eci.12514","article-title":"Additional prognostic value of EAS index in predicting the occurrence of rehospitalizations in chronic heart failure: data from the Daunia Heart Failure registry","volume":"45","author":"Correale","year":"2015","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.ejim.2017.07.016_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2015.05.041","article-title":"Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: data from \u201cmoderate-intensity\u201d statin users in an observational registry on chronic heart failure (Daunia Heart Failure registry)","volume":"194","author":"Brunetti","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/echo.12390","article-title":"Peak myocardial acceleration during isovolumic relaxation time predicts the occurrence of rehospitalization in chronic heart failure: data from the Daunia Heart Failure registry","volume":"31","author":"Correale","year":"2014","journal-title":"Echocardiography"},{"key":"10.1016\/j.ejim.2017.07.016_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12471-013-0430-y","article-title":"Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from the Daunia Heart Failure registry","volume":"21","author":"Correale","year":"2013","journal-title":"Neth Hear J"},{"key":"10.1016\/j.ejim.2017.07.016_bb0040","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1540-8175.2012.01729.x","article-title":"Tissue Doppler time intervals predict the occurrence of rehospitalization in chronic heart failure: data from the Daunia Heart Failure registry","volume":"29","author":"Correale","year":"2012","journal-title":"Echocardiography"},{"key":"10.1016\/j.ejim.2017.07.016_bb0045","first-page":"777","article-title":"Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure registry","volume":"66","author":"Correale","year":"2011","journal-title":"Clinics"},{"key":"10.1016\/j.ejim.2017.07.016_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/CIRCHEARTFAILURE.114.001429","article-title":"\u03b2-Blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis","volume":"7","author":"Thenappan","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2017.07.016_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pupt.2014.11.001","article-title":"Effects of captopril on cardiovascular reflexes and respiratory mechanisms in rats submitted to monocrotaline-induced pulmonary arterial hypertension","volume":"30","author":"Wittmer","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ejim.2017.07.016_bb0060","first-page":"1016","article-title":"Angiotensin converting enzyme inhibitors and pulmonary hypertension","volume":"116","author":"Martiniuc","year":"2012","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"10.1016\/j.ejim.2017.07.016_bb0065","first-page":"40","article-title":"Enalapril treatment of residual pulmonary hypertension in patients operated rheumatic mitral valve defects","volume":"78","author":"Privalova","year":"2000","journal-title":"Klin Med"},{"key":"10.1016\/j.ejim.2017.07.016_bb0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physiolgenomics.00166.2012","article-title":"Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension","volume":"45","author":"Drake","year":"2013","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.ejim.2017.07.016_bb0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jacc.2014.11.050","article-title":"Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension","volume":"65","author":"Perros","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cardfail.2014.08.003","article-title":"Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart","volume":"20","author":"Andersen","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2017.07.016_bb0085","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2012.01.368","article-title":"Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension","volume":"109","author":"So","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0090","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00215514","article-title":"Outcomes of \u03b2-blocker use in pulmonary arterial hypertension: a propensity-matched analysis","volume":"46","author":"Bandyopadhyay","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2017.07.016_bb0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2005.10.013","article-title":"Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension","volume":"130","author":"Provencher","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2017.07.016_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cardfail.2014.02.005","article-title":"Functional improvement in pulmonary arterial hypertension patients treated with ivabradine","volume":"20","author":"Correale","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2017.07.016_bb0110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00392-012-0437-1","article-title":"Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension","volume":"101","author":"Correale","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0115","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/j.ejim.2012.09.008","article-title":"Ivabradine in systemic sclerosis related pulmonary arterial hypertension","volume":"23","author":"Correale","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2017.07.016_bb0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00392-013-0541-x","article-title":"Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?","volume":"102","author":"Correale","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00051215","article-title":"\u03b2-blockers in pulmonary arterial hypertension: evolving concepts of right heart failure","volume":"46","author":"de Man","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2017.07.016_bb0130","doi-asserted-by":"crossref","first-page":"H769","DOI":"10.1152\/ajpheart.00258.2013","article-title":"Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension","volume":"305","author":"Chemla","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00392-012-0516-3","article-title":"Ivabradine: potential clinical applications in critically ill patients","volume":"102","author":"De Santis","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2017.07.016_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/11597400-000000000-00000","article-title":"Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study","volume":"12","author":"Majewski","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2017.07.016_bb0145","first-page":"41","article-title":"Effect of ivabradine on pulmonary hypertension in chronic obstructive pulmonary disease","volume":"52","author":"Akhmetzianova","year":"2012","journal-title":"Kardiologiia"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:54:32Z","timestamp":1535615672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517302844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":28,"alternative-id":["S0953620517302844"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}